Hormone refractory prostate cancer: Management and advances

Cancer Treatment Reviews

Volumn 32, Issue 2, 2006, Pages 90-100

  Sonpavde, Guru ^a   Hutson, Thomas E ^a,b   Berry, William R ^a,c  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c Cancer Centers of North Carolina   (United States)

Author keywords

Biological therapy; Chemotherapy; Hormone refractory prostate cancer; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIANDROGEN; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BICALUTAMIDE; BORTEZOMIB; CALCITRIOL; CANCER VACCINE; CORTICOSTEROID; DIETHYLSTILBESTROL; DN 101; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; EPOTHILONE DERIVATIVE; ESTRADIOL; ESTRAMUSTINE PHOSPHATE; ESTROGEN; FLUTAMIDE; KETOCONAZOLE; MEGESTROL ACETATE; MITOXANTRONE; NAVELBINE; NILUTAMIDE; OBLIMERSEN; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; PROVENGE; SATRAPLATIN; TAXANE DERIVATIVE; TG 4010; UNINDEXED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; MALE; META ANALYSIS; METABOLIC DISORDER; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; PROSTATE CANCER; SEPSIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 33644848317     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.12.005     Document Type: Review

References (87)

1. A. Jemal T. Murray E. Ward et. al. Cancer statistics, 2005 CA Cancer J Clin 55 2005 10-30
2. N. Sharifi J.L. Gulley W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2 2005 238-244
3. W.K. Kelly H.I. Scher M. Mazumdar et. al. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 4 1993 607-615
4. G.J. Bubley M. Carducci W. Dahut et. al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group J Clin Oncol 17 11 1999 3461-3467
5. A.V. D'Amico J. Moul P.R. Carroll et. al. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer J Urol 173 5 2005 1572-1576
6. M.R. Smith F. Kabbinavar F. Saad et. al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 13 2005 2918-2925
7. D'Amico AV, Halabi S, Vogelzang NJ, Small EJ. A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials. In: Journal of Clinical Oncology 2004 ASCO Annual meeting proceedings (post-meeting edition), vol. 22, No. 14S (July 15 Suppl); 2004. p. 4506.
8. P. Therasse S.G. Arbuck E.A. Eisenhauer et. al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205-216
9. J.E. Fowler Jr. W.F. Whitmore Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone J Urol 126 3 1981 372-375
10. C.D. Taylor P. Elson D.L. Trump Importance of continued testicular suppression in hormone-refractory prostate cancer J Clin Oncol 11 11 1993 2167-2172
11. M. Hussain M. Wolf E. Marshall et. al. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A southwest oncology group report J Clin Oncol 12 9 1994 1868-1875
12. N.A. Dawson Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials J Clin Oncol 16 10 1998 3398-3405
13. J.E. Fowler Jr. P. Pandey L.E. Seaver T.P. Feliz Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment J Urol 154 2 Pt 1 1995 448-453
14. H.I. Scher C. Liebertz W.K. Kelly et. al. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease J Clin Oncol 15 8 1997 2928-2938
15. R. Joyce M.A. Fenton P. Rode et. al. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy J Urol 159 1 1998 149-153
16. N.A. Dawson M. Conaway S. Halabi et. al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and leukemia group B study 9181 Cancer 88 4 2000 825-834
17. W.K. Kelly H.I. Scher Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome J Urol 149 3 1993 607-609
18. E.J. Small S. Srinivas The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer Cancer 76 8 1995 1428-1434
19. P.F. Schellhammer P. Venner G.P. Haas et. al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade J Urol 157 5 1997 1731-1735
20. T. Hara J. Miyazaki H. Araki et. al. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome Cancer Res 63 1 2003 149-153
21. E.J. Small A.D. Baron L. Fippin D. Apodaca Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal J Urol 157 4 1997 1204-1207
22. E.J. Small S. Halabi N.A. Dawson et. al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583) J Clin Oncol 22 6 2004 1025-1033
23. K.A. Harris V. Weinberg R.A. Bok et. al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer J Urol 168 2 2002 542-545
24. M. Shahidi A.R. Norman J. Gadd et. al. Prospective review of diethylstilbestrol in advanced prostate cancer no longer responding to androgen suppression Proc Am Soc Clin Oncol 2001 [abstract 2455]
25. E. Rosenbaum M. Wygoda M. Gips et. al. Diethystilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade Proc Am Soc Clin Oncol 2000 [abstract 1372]
26. L.B. Bland M. Garzotto T.G. DeLoughery et. al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma Cancer 103 4 2005 717-723
27. W.K. Oh D.J. George K. Hackmann et. al. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer Urology 57 1 2001 122-126
28. R.S. DiPaola H. Zhang G.H. Lambert et. al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer N Engl J Med 339 12 1998 785-791
29. R. Benson B. Hartley-Asp Mechanisms of action and clinical uses of estramustine Cancer Invest 8 1990 375-380
30. F. Dexeus C.J. Logothetics M.L. Samuels et. al. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer Cancer Treat Rep 69 1985 885-886
31. S. Oudard A. Caty Y. Humblet et. al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer Ann Oncol 12 6 2001 847-852
32. G. Hudes L. Einhorn E. Ross et. al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier oncology group and Fox Chase network phase III trial J Clin Oncol 17 10 1999 3160-3166
33. G. Hudes E. Ross B. Roth et. al. Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: Final report of a Hoosier oncology group and Fox Chase network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate Proc Am Soc Clin Oncol 2002 [abstract 704]
34. G.M. Lubiniecki J.A. Berlin R.B. Weinstein D.J. Vaughn Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: Results of a meta-analysis Cancer 101 12 2004 2755-2759
35. A. Yagoda R.C. Watson R.B. Natale et. al. A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II Cancer 44 5 1979 1553-1562
36. L. Miglietta L. Cannobbio F. Boccardo Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: A critical analysis of drug activity Anticancer Res 15 6B 1995 2825-2828
37. G. Steineck V. Reuter W.K. Kelly et. al. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements Acta Oncol 41 7-8 2002 668-674
38. W.K. Kelly T. Curley S. Slovin et. al. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer J Clin Oncol 19 1 2001 44-53
39. W.K. Oh S. Halabi W.K. Kelly et. al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and leukemia group B 99813 Cancer 98 12 2003 2592-2598
40. C. Rangel H. Matzkin M.S. Soloway Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer Urology 39 1992 577-582
41. B. Neri G. Barbagli P. Bellesi et. al. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer Anticancer Res 17 1997 3817-3820
42. K.A. Harris E. Harney E.J. Small Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer Clin Prostate Cancer 1 1 2002 37-41
43. I.F. Tannock D. Osoba M.R. Stockler et. al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 6 1996 1756-1764
44. P.W. Kantoff S. Halabi M. Conaway et. al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study J Clin Oncol 17 8 1999 2506-2513
45. W. Berry S. Dakhil M. Modiano et. al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer J Urol 168 6 2002 2439-2443
46. B.J. Roth B.Y. Yeap G. Wilding et. al. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group Cancer 72 8 1993 2457-2460
47. G.R. Hudes F. Nathan C. Khater et. al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer J Clin Oncol 15 9 1997 3156-3163
48. W.R. Berry J.W. Hathorn S.R. Dakhil et. al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer Clin Prostate Cancer 3 2 2004 104-111
49. J. Picus M. Schultz Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results Semin Oncol 26 5 Suppl 17 1999 14-18
50. W. Berry S. Dakhil M.A. Gregurich L. Asmar Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate Semin Oncol 28 4 Suppl 15 2001 8-15
51. T.M. Beer W.C. Pierce B.A. Lowe W.D. Henner Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer Ann Oncol 12 9 2001 1273-1279
52. D.M. Savarese S. Halabi V. Hars et. al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and leukemia group B J Clin Oncol 19 9 2001 2509-2516
53. D.P. Petrylak R. Macarthur J. O'Connor et. al. Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone-refractory prostate cancer Semin Oncol 26 5 Suppl 17 1999 28-33
54. V.J. Sinibaldi M.A. Carducci S. Moore-Cooper et. al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 5 2002 1457-1465
55. I.F. Tannock R. de Wit W.R. Berry et. al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 15 2004 1502-1512
56. D.P. Petrylak C.M. Tangen M.H. Hussain et. al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 2004 1513-1520
57. S. Oudard E. Banu P. Beuzeboc et. al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer J Clin Oncol 23 15 2005 3343-3351
58. M.L. Ioffe E. White D.A. Nelson et. al. Epothilone induced cytotoxicity is dependent on p53 status in prostate cells Prostate 61 2004 243-247
59. M.D. Galsky E.J. Small W.K. Oh et. al. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer J Clin Oncol 23 7 2005 1439-1446
60. C.N. Sternberg P. Whelan J. Hetherington et. al. Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer Oncology 68 1 2005 2-9
61. J.B. Nelson A.A. Nabulsi N.J. Vogelzang et. al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan J Urol 169 3 2003 1143-1149
62. N.J. Vogelzang J.B. Nelson C.C. Schulman et. al. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer Proc Am Soc Clin Oncol 2005 [abstract 4563]
63. W.D. Figg W. Dahut P. Duray et. al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 2001 1888-1893
64. W.L. Dahut J.L. Gulley P.M. Arlen et. al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 2004 2532-2539
65. Retter AS, Ando Y, Price DK, et al. Follow-up analysis of a randomized phase II study of docetaxel and thalidomide in androgen-independent prostate cancer: Updated survival data and stratification by CYP2C19 mutation status. In: Proceedings of the prostate cancer symposium; 2005 [abstract 265].
66. J. Picus S. Halabi B. Rini et. al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006 Proc Am Soc Clin Oncol 22 2003 393 [abstract 1578]
67. R.H. Getzenberg B.W. Light P.E. Lapco et. al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system Urology 50 1997 999-1006
68. T.M. Beer K.M. Eilers M. Garzotto et. al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer J Clin Oncol 21 1 2003 123-128
69. T.M. Beer C.W. Ryan P.M. Venner et. al. Interim results from ASCENT: A double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer Proc Am Soc Clin Oncol 2005 [abstract 4516]
70. T.J. McDonnell P. Troncoso S.M. Brisbay et. al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer Cancer Res 52 1992 6940-6944
71. A.W. Tolcher K. Chi J. Kuhn et. al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer Clin Cancer Res 11 10 2005 3854-3861
72. L.V. July M. Akbari T. Zellweger et. al. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy Prostate 50 2002 179-188
73. E.J. Small P.F. Schellhammer C.S. Higano et. al. Results of a placebo-controlled phase III trial of immunotherapy with APC8015 for patients with hormone refractory prostate cancer Proc Am Soc Clin Oncol 2005 [abstract 4500]
74. R. Dreicer R. Ahman A. Pantuck et. al. Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) In prostate cancer patients with biochemical failure Proc Am Soc Clin Oncol 2005 [abstract 4518]
75. H.L. Kaufman W. Wang J. Manola et. al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the eastern cooperative oncology group J Clin Oncol 22 11 2004 2122-2132
76. J. Simons C. Higano D. Smith et. al. Clinical and immunologic findings in a phase 2 study of a GM-CSF-secreting prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer Proc Am Soc Clin Oncol 2005 [abstract 2517]
77. H. Liu P. Moy S. Kim et. al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res 57 1997 3629-3634
78. N.H. Bander M.I. Milowsky D.M. Nanus et. al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J Clin Oncol 23 21 2005 4591-4601
79. M.I. Milowsky D.M. Nanus L. Kostakoglu et. al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 13 2004 2522-2531
80. C.N. Papandreou D.D. Daliani D. Nix et. al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer J Clin Oncol 22 11 2004 2108-2121
81. Dreicer R, Roth B, Petrylak D. Bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer: A phase 1/2 study. In: Proceedings of the prostate cancer symposium; 2005 [abstract 250].
82. C.M. Canil M.J. Moore E. Winquist et. al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada - clinical trials group J Clin Oncol 23 3 2005 455-460
83. A. Ziada A. Barqawi L.M. Glode et. al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 4 2004 332-337
84. P.N. Lara Jr. K.G. Chee J. Longmate et. al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma:fInal results from the California cancer consortium screening and phase II trial Cancer 100 10 2004 2125-2131
85. K. Rao S. Goodin M.J. Levitt et. al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer Prostate 62 2 2005 115-122
86. P. Mathew P.F. Thall D. Jones et. al. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer J Clin Oncol 22 16 2004 3323-3329
87. W.G. Nelson A.M. De Marzo W.B. Isaacs Mechanisms of disease: Prostate cancer N Engl J Med 349 2003 366-381